NVA237 treatment was statistically significantly superior to
placebo with respect to exercise endurance time after 3 weeks
(on Day 21) of treatment. The LSM treatment difference on
Day 21 between treatment groups was 88.9 seconds, corresponding
to an approximately 21% difference (P , 0.001;
Figure 2). On Day 1, the LSM treatment difference between
groups was 43.1 seconds, corresponding to an approximately
10% difference (P , 0.001; Figure 2).